Compare · GLP-1 agonist
Mazdutide vs Orforglipron
Both are glp-1 agonist compounds. Here's how they line up on the evidence — graded the same way.
| Mazdutide | Orforglipron | |
|---|---|---|
| Evidence | Preliminary human | Strong human |
| Class | GLP-1 agonist | GLP-1 agonist |
| Summary | A GLP-1/glucagon dual agonist approved in China for weight loss and diabetes, with genuine RCT evidence that is still sponsor-funded and single-country. | An oral, non-peptide (small-molecule) GLP-1 receptor agonist, FDA-approved in April 2026 as Foundayo for chronic weight management. It is a once-daily pill with no food or timing restrictions — not a peptide, and not an injectable. |
| Full profile → | Full profile → |
Mazdutide
Mazdutide is an injectable drug for weight loss and type 2 diabetes that activates two metabolic hormone receptors at once. Unlike most of the attention-grabbing GLP-1 compounds, it is not stuck at the press-release stage: it has a published Phase 3 trial in a major journal and is actually approved…
Orforglipron
Orforglipron (brand name Foundayo) is a GLP-1 receptor agonist — the same drug class as semaglutide and tirzepatide — but with one defining difference: it is a small molecule, not a peptide, and it is taken as a once-daily pill rather than an injection. In April 2026 the FDA approved it for chronic…